•  
  •  
 

Authors

Mariano Berro, HSCT Unit, Hospital Universitario Austral, Pilar, ArgentinaFollow
Nelson Hamerschlak, HSCT Unit, Hospital Israelita Albert Einstein, San Pablo, Brazil
Vera Milovic, HSCT Unit, Hospital Aleman, Buenos Aires, Argentina
Belen Castro, HSCT Unit, Hospital Privado de Cordoba, Cordoba, Argentina
Andres P. García, HSCT Unit, Hospital Privado de Cordoba, Cordoba, Argentina
Gonzalo Ferini, HSCT Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Jose J. Real, HSCT Unit, Hospital Aleman, Buenos Aires, Argentina
Adriana Vitriu, HSCT Unit, Instituto Alexander Fleming, Buenos Aires, Argentina
Alberto C. Gimenez, HSCT Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Georgina Bendek, HSCT Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Sebastian Yantorno, HSCT Unit, Hospital Italiano La Plata, La Plata, Argentina
Juliana R. Martinez, HSCT Unit, FUNDALEU, Buenos Aires, Argentina
Martin Saslavsky, HSCT Unit, CETRAMOR, Rosario, Argentina
Sol Jarchum, HSCT Unit, Sanatorio Allende, Cordoba, Argentina
Amalia Cerutti, HSCT Unit, Sanatorio Britanico, Rosario, Argentina
Cinthya Correa da S., HSCT Unit, Hospital Israelita Albert Einstein, San Pablo, Brazil
Morgani Rodrigues, HSCT Unit, Hospital Israelita Albert Einstein, San Pablo, Brazil
Leandro Riera, HSCT Unit, CEMIC, Buenos Aires, Argentina
Jorge Arbelbide, HSCT Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Gustavo Kusminsky, HSCT Unit, Hospital Universitario Austral, Pilar, Argentina
Lisa A. Basquiera, HSCT Unit, Hospital Privado de Cordoba, Cordoba, Argentina

Abstract

Background and objectives: Allogeneic stem cell transplantation (Allo-SCT) in elderly patients is a growing practice. We aimed to determine the graft-versus-host disease (GVHD) relapse-free survival (GRFS) in patients ≥65 years who underwent Allo-SCT in two countries from Latin America. Patients and methods: We performed a retrospective analysis of patients ≥65 years who underwent Allo-SCT in Argentina and Brazil from 2007 to 2019. Results: Ninety-eight patients were evaluated, with primary diagnoses of acute myeloid leukemia and myelodysplastic syndrome; 30% of patients had a hematopoietic cell transplant-comorbidity index (HCT-CI) score ≥3 and 49% were in complete remission. Donor types included matched sibling (n ¼ 41), matched unrelated (n ¼ 31), and haploidentical (HID; n ¼ 26) donors. The conditioning regimen was myeloablative in 28 patients (14 busulfan pharmacokinetically [PK]-guided) and reduced-intensity in 70 patients. The two-year non-relapse mortality (NRM) was 29%, with a higher NRM in melphalan-based compared to other conditionings (51% vs. 33%, p ¼ 0.02). The two-year relapse rate was 24%, with a reduction in PK-guided busulfan (0% vs. 28%, p ¼ 0.03). The two-year overall survival (OS) and GRFS was 52% and 38%, respectively, with a significant reduction in GRFS in HCT-CI ≥3 (27% vs. others 42%, p ¼ 0.02) and donors ≥40 years (29% vs.55%, p ¼ 0.02). These variables remained significantly associated with GRFS after multivariate analysis. Conclusion: In this cohort of elderly patients from Argentina and Brazil undergoing Allo-SCT, donor age and comorbidities significantly influenced GRFS. The role of the conditioning regimen in this population deserves further investigation.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS